Systematic review. Cochrane.
Overall, DAAs (direct-acting antivirals) on the market or under development do not seem to have any
effects on risk of serious adverse events. Simeprevir may have
beneficial effects on risk of serious adverse event. In all remaining
analyses, we could neither confirm nor reject that DAAs had any clinical
effects. DAAs seemed to reduce the risk of no sustained virological
response.
The clinical relevance of the effects of DAAs on no sustained
virological response is questionable, as it is a non-validated surrogate
outcome. All trials and outcome results were at high risk of bias, so
our results presumably overestimate benefit and underestimate harm. The
quality of the evidence was very low.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012143.pub2/full
Crítica a la revisión Cochrane sobre los antivirales en la hepatitis
C. European Association for the Study of the Liver.